New AdvaMed Chair Lobo: Devices Has A Good Story To Tell

Nadim Yared Will Be A Hard Act To Follow For New AdvaMed Chair Kevin Lobo

A whirlwind two-year stint as chair of the US medtech industry association, AdvaMed, came to end this month for CVRx’e energetic CEO Nadim Yared. Incoming chair, Stryker’s Kevin Lobo, comes from an altogether much larger concern, but he will continue Yared’s legacy of supporting SMEs, as well as bringing his own agenda to the role.

Stryker CEO Kevin Lobo
Kevin Lobo, CEO of Stryker and new AdvaMed chair • Source: Advamed/Stryker

CVRX CEO Nadim Yared will be a hard act to follow as AdvaMed chair, as his list of accomplishments over the past two years, as well as his ability to maintain the spotlight on the medtech industry in the US and beyond, have shown. In Kevin Lobo, CEO of Stryker Corp., the industry has a leader who will continue to push back the boundaries for SMEs, as well as developing his own agenda points.

Lobo’s two-year tenure was announced on March 27, and he knows that the 2012 medical device excise tax will continue...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By 

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.